Naegeli Hanspeter, Birch Andrew Nicholas, Casacuberta Josep, De Schrijver Adinda, Gralak Mikołaj Antoni, Jones Huw, Manachini Barbara, Messéan Antoine, Nielsen Elsa Ebbesen, Nogué Fabien, Robaglia Christophe, Rostoks Nils, Sweet Jeremy, Tebbe Christoph, Visioli Francesco, Wal Jean-Michel, Álvarez Fernando, Ardizzone Michele, Fernandez Dumont Antonio, Gómez Ruiz José Ángel, Papadopoulou Nikoletta, Paraskevopoulos Konstantinos
EFSA J. 2018 Aug 2;16(8):e05346. doi: 10.2903/j.efsa.2018.5346. eCollection 2018 Aug.
Soybean MON 87751 was developed through -mediated transformation to provide protection certain specific lepidopteran pests by the expression of the Cry1A.105 and Cry2Ab2 proteins derived from . The molecular characterisation data and bioinformatic analyses did not identify issues requiring assessment for food and feed safety. None of the compositional, agronomic and phenotypic differences identified between soybean MON 87751 and the conventional counterpart required further assessment. The GMO Panel did not identify safety concerns regarding the toxicity and allergenicity of the Cry1A.105 and Cry2Ab2 proteins as expressed in soybean MON 87751, and found no evidence that the genetic modification might significantly change the overall allergenicity of soybean MON 87751. The nutritional impact of soybean MON 87751-derived food and feed is expected to be the same as those derived from the conventional counterpart and non-GM commercial reference varieties. The GMO Panel concludes that soybean MON 87751, as described in this application, is nutritionally equivalent to and as safe as the conventional counterpart and the non-GM soybean reference varieties tested, and no post-market monitoring of food and feed is considered necessary. In the case of accidental release of viable soybean MON 87751 seeds into the environment, soybean MON 87751 would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of soybean MON 87751. In conclusion, soybean MON 87751, as described in this application, is as safe as its conventional counterpart and the tested non-GM soybean reference varieties with respect to potential effects on human and animal health and the environment.
大豆MON 87751是通过[此处信息缺失]介导的转化培育而成，通过表达源自[此处信息缺失]的Cry1A.105和Cry2Ab2蛋白来抵御某些特定的鳞翅目害虫。分子特征数据和生物信息学分析未发现需要进行食品和饲料安全性评估的问题。大豆MON 87751与其传统对照品种之间所确定的成分、农艺和表型差异均无需进一步评估。转基因生物小组未发现大豆MON 87751中表达的Cry1A.105和Cry2Ab2蛋白的毒性和致敏性存在安全问题，也未发现有证据表明基因改造可能会显著改变大豆MON 87751的整体致敏性。预计源自大豆MON 87751的食品和饲料对营养的影响与源自传统对照品种和非转基因商业参考品种的食品和饲料相同。转基因生物小组得出结论，本申请所述的大豆MON 87751在营养上等同于所测试的传统对照品种和非转基因大豆参考品种，并且同样安全，无需对食品和饲料进行上市后监测。如果大豆MON 87751的活种子意外释放到环境中，大豆MON 87751不会引发环境安全问题。上市后环境监测计划和报告间隔符合大豆MON 87751的预期用途。总之，就对人类和动物健康以及环境的潜在影响而言，本申请所述的大豆MON 87751与其传统对照品种和所测试的非转基因大豆参考品种一样安全。
